Goals & Objectives
Education & Resources▼
Find a Clinician
Refer a Colleague
According to Dr Harsh, which of the following is true of bremelanotide?
a. FDA approved in June 2019
b. Treats generalized, acquired hypoactive sexual desire disorder in premenopausal women
c. Subcutaneous use 45 minutes before sexual activity
d. All of the above
Your answers are confidential and will be used for educational purposes only.